06:31:17 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



Sirona Biochem Corp
Symbol SBM
Shares Issued 208,761,737
Close 2019-06-11 C$ 0.50
Market Cap C$ 104,380,869
Recent Sedar Documents

Sirona to test TFC-1067 at higher concentration

2019-06-11 06:22 ET - News Release

Dr. Howard Verrico reports

SIRONA BIOCHEM REPORTS APPROVAL TO TEST HIGHER CONCENTRATIONS OF SKIN LIGHTENING COMPOUND TFC-1067

Sirona Biochem Corp. will assess its novel skin lightener, TFC-1067, at a concentration three times higher than what was used in the previous clinical trial. Higher dosing is expected to have increased efficacy, but also the potential to work more quickly than the clinically effective dose established for TFC-1067. This positive development is of substantial commercial interest to potential cosmetic partners in North America and China which share Sirona's goal to maximize efficacy without compromising safety.

Previous maximum dosing levels were limited due to technical issues with the standard regulatory in vitro test used to assess TFC-1067 for skin irritation. A solution to these technical issues has been developed. Sirona's consultant safety assessor at CEHTRA has now recommended further testing with up to a three times higher dose. Several higher doses will be assessed by Idea Lab, experts in safety testing of cosmetics. If the in vitro results of the higher concentrations continue to show no evidence for skin irritation, Sirona will proceed to preparation for clinical testing on humans.

"The clinical effect of TFC-1067 to lessen dark spots or have an overall brightening effect is largely dose dependent," reported Dr. Howard Verrico, chief executive officer of Sirona Biochem. "We anticipate TFC-1067 will be used at higher doses without adverse effects. While we are pleased with the excellent clinical results achieved so far, being able to test at significantly higher concentrations will likely lead to better clinical effectiveness, potentially faster results and a better range of consumer dosing options."

"We knew the standard regulatory tests prevented us from utilizing the full potential of TFC-1067 as a skin lightener. We anticipate we will proceed in the future to test our improved formulation combined with higher concentrations of TFC-1067 in further clinical trials. Such testing can be conducted either independently by Sirona or through our anticipated partnerships," Dr. Verrico added.

The global skin lightening market is expected to reach $31.2-billion (U.S.) by 2024.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules, with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.